Literature DB >> 24074785

Mutational analysis of breast cancer: guiding personalized treatments.

Matthew J Ellis1.   

Abstract

The application of high throughput techniques to profile DNA, RNA and protein in breast cancer samples from hundreds of patients has profoundly increased our knowledge of the disease. However there remain many knowledge gaps that will require a long process of extended clinical correlation studies, deeper integrated 'omic analysis and functional annotation to address. This article reviews conclusions from recent breast cancer 'omics profiling' papers and considers pathways forward for extracting medically valuable information from large dimension data sets.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Genomics; Somatic mutation; Therapeutic road map; Whole genome sequencing

Mesh：

Substances：

Year:  2013        PMID： 24074785      PMCID： PMC3787523          DOI： 10.1016/j.breast.2013.07.003

Source DB:  PubMed          Journal:  Breast        ISSN： 0960-9776            Impact factor:   4.380


  25 in total

1.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.

Authors:  Patrick J Roberts; John E Bisi; Jay C Strum; Austin J Combest; David B Darr; Jerry E Usary; William C Zamboni; Kwok-Kin Wong; Charles M Perou; Norman E Sharpless
Journal:  J Natl Cancer Inst       Date:  2012-02-01       Impact factor: 13.506

3.  PIKing the right isoform: the emergent role of the p110beta subunit in breast cancer.

Authors:  Silvia Carvalho; Fernanda Milanezi; José Luís Costa; Isabel Amendoeira; Fernando Schmitt
Journal:  Virchows Arch       Date:  2010-02-04       Impact factor: 4.064

4.  Genome remodelling in a basal-like breast cancer metastasis and xenograft.

Authors:  Li Ding; Matthew J Ellis; Shunqiang Li; David E Larson; Ken Chen; John W Wallis; Christopher C Harris; Michael D McLellan; Robert S Fulton; Lucinda L Fulton; Rachel M Abbott; Jeremy Hoog; David J Dooling; Daniel C Koboldt; Heather Schmidt; Joelle Kalicki; Qunyuan Zhang; Lei Chen; Ling Lin; Michael C Wendl; Joshua F McMichael; Vincent J Magrini; Lisa Cook; Sean D McGrath; Tammi L Vickery; Elizabeth Appelbaum; Katherine Deschryver; Sherri Davies; Therese Guintoli; Li Lin; Robert Crowder; Yu Tao; Jacqueline E Snider; Scott M Smith; Adam F Dukes; Gabriel E Sanderson; Craig S Pohl; Kim D Delehaunty; Catrina C Fronick; Kimberley A Pape; Jerry S Reed; Jody S Robinson; Jennifer S Hodges; William Schierding; Nathan D Dees; Dong Shen; Devin P Locke; Madeline E Wiechert; James M Eldred; Josh B Peck; Benjamin J Oberkfell; Justin T Lolofie; Feiyu Du; Amy E Hawkins; Michelle D O'Laughlin; Kelly E Bernard; Mark Cunningham; Glendoria Elliott; Mark D Mason; Dominic M Thompson; Jennifer L Ivanovich; Paul J Goodfellow; Charles M Perou; George M Weinstock; Rebecca Aft; Mark Watson; Timothy J Ley; Richard K Wilson; Elaine R Mardis
Journal:  Nature       Date:  2010-04-15       Impact factor: 49.962

5.  PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.

Authors:  Robert J Crowder; Chanpheng Phommaly; Yu Tao; Jeremy Hoog; Jingqin Luo; Charles M Perou; Joel S Parker; Melinda A Miller; David G Huntsman; Li Lin; Jacqueline Snider; Sherri R Davies; John A Olson; Mark A Watson; Anthony Saporita; Jason D Weber; Matthew J Ellis
Journal:  Cancer Res       Date:  2009-04-14       Impact factor: 12.701

6.  Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent.

Authors:  Jing Ni; Qingsong Liu; Shaozhen Xie; Coby Carlson; Thanh Von; Kurt Vogel; Steve Riddle; Cyril Benes; Michael Eck; Thomas Roberts; Nathanael Gray; Jean Zhao
Journal:  Cancer Discov       Date:  2012-04-12       Impact factor: 39.397

7.  The landscape of cancer genes and mutational processes in breast cancer.

Authors:  Philip J Stephens; Patrick S Tarpey; Helen Davies; Peter Van Loo; Chris Greenman; David C Wedge; Serena Nik-Zainal; Sancha Martin; Ignacio Varela; Graham R Bignell; Lucy R Yates; Elli Papaemmanuil; David Beare; Adam Butler; Angela Cheverton; John Gamble; Jonathan Hinton; Mingming Jia; Alagu Jayakumar; David Jones; Calli Latimer; King Wai Lau; Stuart McLaren; David J McBride; Andrew Menzies; Laura Mudie; Keiran Raine; Roland Rad; Michael Spencer Chapman; Jon Teague; Douglas Easton; Anita Langerød; Ming Ta Michael Lee; Chen-Yang Shen; Benita Tan Kiat Tee; Bernice Wong Huimin; Annegien Broeks; Ana Cristina Vargas; Gulisa Turashvili; John Martens; Aquila Fatima; Penelope Miron; Suet-Feung Chin; Gilles Thomas; Sandrine Boyault; Odette Mariani; Sunil R Lakhani; Marc van de Vijver; Laura van 't Veer; John Foekens; Christine Desmedt; Christos Sotiriou; Andrew Tutt; Carlos Caldas; Jorge S Reis-Filho; Samuel A J R Aparicio; Anne Vincent Salomon; Anne-Lise Børresen-Dale; Andrea L Richardson; Peter J Campbell; P Andrew Futreal; Michael R Stratton
Journal:  Nature       Date:  2012-05-16       Impact factor: 49.962

8.  Whole-genome analysis informs breast cancer response to aromatase inhibition.

Authors:  Matthew J Ellis; Li Ding; Dong Shen; Jingqin Luo; Vera J Suman; John W Wallis; Brian A Van Tine; Jeremy Hoog; Reece J Goiffon; Theodore C Goldstein; Sam Ng; Li Lin; Robert Crowder; Jacqueline Snider; Karla Ballman; Jason Weber; Ken Chen; Daniel C Koboldt; Cyriac Kandoth; William S Schierding; Joshua F McMichael; Christopher A Miller; Charles Lu; Christopher C Harris; Michael D McLellan; Michael C Wendl; Katherine DeSchryver; D Craig Allred; Laura Esserman; Gary Unzeitig; Julie Margenthaler; G V Babiera; P Kelly Marcom; J M Guenther; Marilyn Leitch; Kelly Hunt; John Olson; Yu Tao; Christopher A Maher; Lucinda L Fulton; Robert S Fulton; Michelle Harrison; Ben Oberkfell; Feiyu Du; Ryan Demeter; Tammi L Vickery; Adnan Elhammali; Helen Piwnica-Worms; Sandra McDonald; Mark Watson; David J Dooling; David Ota; Li-Wei Chang; Ron Bose; Timothy J Ley; David Piwnica-Worms; Joshua M Stuart; Richard K Wilson; Elaine R Mardis
Journal:  Nature       Date:  2012-06-10       Impact factor: 49.962

9.  Massive genomic rearrangement acquired in a single catastrophic event during cancer development.

Authors:  Philip J Stephens; Chris D Greenman; Beiyuan Fu; Fengtang Yang; Graham R Bignell; Laura J Mudie; Erin D Pleasance; King Wai Lau; David Beare; Lucy A Stebbings; Stuart McLaren; Meng-Lay Lin; David J McBride; Ignacio Varela; Serena Nik-Zainal; Catherine Leroy; Mingming Jia; Andrew Menzies; Adam P Butler; Jon W Teague; Michael A Quail; John Burton; Harold Swerdlow; Nigel P Carter; Laura A Morsberger; Christine Iacobuzio-Donahue; George A Follows; Anthony R Green; Adrienne M Flanagan; Michael R Stratton; P Andrew Futreal; Peter J Campbell
Journal:  Cell       Date:  2011-01-07       Impact factor: 41.582

10.  A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types.

Authors:  Stephen Jamieson; Jack U Flanagan; Sharada Kolekar; Christina Buchanan; Jackie D Kendall; Woo-Jeong Lee; Gordon W Rewcastle; William A Denny; Ripudaman Singh; James Dickson; Bruce C Baguley; Peter R Shepherd
Journal:  Biochem J       Date:  2011-08-15       Impact factor: 3.857
View more
  7 in total

1.  Predictive value of microtubule-associated protein Tau in patients with recurrent and metastatic breast cancer treated with taxane-containing palliative chemotherapy.

Authors:  Jie Zhou; Shikun Qian; Hongsheng Li; Weixing He; Xiaojun Tan; Qiong Zhang; Guodong Han; Guiquan Chen; Rongcheng Luo
Journal:  Tumour Biol       Date:  2015-03-14

2.  Exploiting DNA repair defects in triple negative breast cancer to improve cell killing.

Authors:  Kevin J Lee; Elise Mann; Griffin Wright; Cortt G Piett; Zachary D Nagel; Natalie R Gassman
Journal:  Ther Adv Med Oncol       Date:  2020-09-18       Impact factor: 8.168

3.  Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mutated Metastatic Breast Cancer.

Authors:  Swapnil Parmar; Jamie M Keck; Ben Kong; Regan Look; Brett Johnson; Janice Patterson; Marilyne Labrie; Alexander R Guimaraes; Christopher L Corless; Carol Beadling; Annette Kolodzie; Raymond Bergan; Joe W Gray; Gordon B Mills; Zahi I Mitri
Journal:  JCO Precis Oncol       Date:  2021-01-08

Review 4.  The Role of Innate Immunity in the Pathogenesis of Breast Cancer.

Authors:  Damir Grebić; Tamara Gulić; Alma Starčević; Manuela Alvirović; Gordana Blagojević Zagorac; Petra Valković Zujić; Danijela Veljković Vujaklija
Journal:  Breast Care (Basel)       Date:  2020-05-04       Impact factor: 2.860

Review 5.  Patient-derived xenograft models of breast cancer and their predictive power.

Authors:  James R Whittle; Michael T Lewis; Geoffrey J Lindeman; Jane E Visvader
Journal:  Breast Cancer Res       Date:  2015-02-10       Impact factor: 6.466

6.  Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital.

Authors:  Aditya Bardia; John A Iafrate; Tilak Sundaresan; Jerry Younger; Valentina Nardi
Journal:  Oncologist       Date:  2016-08-22

Review 7.  Analysis of different HER-2 mutations in breast cancer progression and drug resistance.

Authors:  Zijia Sun; Yaqin Shi; Yan Shen; Lulu Cao; Wenwen Zhang; Xiaoxiang Guan
Journal:  J Cell Mol Med       Date:  2015-08-25       Impact factor: 5.310
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.